Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on June 15, 2026 to five new non-executive employees under its 2025 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on June 15, 2026 to five new non-executive employees under its 2025 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

The employees received an aggregate of 1,397 time-based RSUs, vesting in four equal annual installments, subject to continued employment.

Argus Jun 23 session

+0.11% close to close Open Argus

Details

News Market Reaction – MDGL

In the Jun 23 session, MDGL gained 0.11%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine equity inducement awards totaling 1,397 RSUs to 5 new employees, v...

Analysis

This announcement details routine equity inducement awards totaling 1,397 RSUs to 5 new employees, vesting over 4 years. It modestly expands equity-based compensation while short interest remains elevated, making future governance or compensation changes worth monitoring.

Key Figures

Inducement employees: 5 new non-executive employees Inducement RSUs granted: 1,397 time-based restricted stock units Vesting schedule: 4 equal annual installments

Inducement employees

5 new non-executive employees

Recipients of June 15, 2026 equity inducement awards

Inducement RSUs granted

1,397 time-based restricted stock units

Aggregate equity awards under Madrigal’s 2025 Inducement Plan

Vesting schedule

4 equal annual installments

RSUs vest on first through fourth anniversaries of grant date

Historical Context

5 past events · Latest: Jun 04

5 events

1. Jun 04

   Inducement grants

   24h Move

   -1.2%

   Equity inducement RSUs granted to new employees under the 2025 Inducement Plan.

2. Jun 03

   Conference participation

   24h Move

   +7.8%

   Announcement of presentation at major Goldman Sachs health care investor conference.

3. May 27

   Clinical data update

   24h Move

   +0.7%

   Phase 3 and real-world data showing Rezdiffra reduced key MASH risk markers.

4. May 21

   Inducement grants

   24h Move

   +0.7%

   Restricted stock unit inducement awards to new non-executive employees.

5. May 20

   Upcoming data at EASL

   24h Move

   -1.3%

   Planned presentation of new Rezdiffra data on cardiovascular and portal hypertension risk.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

metabolic dysfunction-associated steatohepatitis (mash), nasdaq listing rule 5635(c)(4), restricted stock units, inducement awards

4 terms

metabolic dysfunction-associated steatohepatitis (mash) medical

"novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced"

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver condition characterized by inflammation and fat buildup caused by metabolic issues like obesity and insulin resistance. It can lead to liver damage over time, similar to rust gradually weakening metal. Because it is linked to widespread health problems such as diabetes and heart disease, MASH is becoming an important factor in overall health risks and healthcare costs, which can impact economic and investment considerations.

nasdaq listing rule 5635(c)(4) regulatory

"equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"The new employees received, in the aggregate, 1,397 time-based restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

inducement awards financial

"it granted equity awards on June 15, 2026 to five new non-executive employees as equity inducement awards under the terms"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2026 to five new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 1,397 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity awards did Madrigal (NASDAQ:MDGL) grant on June 15, 2026?

Madrigal granted time-based restricted stock unit awards to five new non-executive employees. According to Madrigal, these equity inducement awards were made under the 2025 Inducement Plan as a material inducement for the employees to accept employment with the company.

How many restricted stock units did Madrigal (MDGL) grant under the 2025 Inducement Plan in June 2026?

Madrigal granted an aggregate of 1,397 time-based restricted stock units to new employees. According to Madrigal, these RSUs were issued as equity inducement awards for five non-executive hires under the company’s 2025 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).

What is the vesting schedule for Madrigal (MDGL) inducement RSUs granted on June 15, 2026?

The inducement RSUs vest in four equal annual installments on each of the first through fourth anniversaries. According to Madrigal, vesting of all awards is contingent on each employee’s continued employment with the company on the applicable vesting date.

Why did Madrigal Pharmaceuticals use Nasdaq Listing Rule 5635(c)(4) for the June 2026 MDGL inducement awards?

Madrigal used Nasdaq Listing Rule 5635(c)(4) to grant equity awards as a material inducement to new hires. According to Madrigal, the independent Compensation Committee approved these RSUs for five non-executive employees under the 2025 Inducement Plan.

Are the June 15, 2026 Madrigal (MDGL) inducement RSUs subject to continued employment?

Yes, vesting of the June 15, 2026 inducement RSUs requires continued employment at each vesting date. According to Madrigal, all awards vest over four years in equal tranches, contingent on each employee remaining employed on the relevant anniversary.